0V0 Stock Chart & Stats
€2.47
-€0.20(-5.41%)
At close: 4:00 PM EST
€2.47
-€0.20(-5.41%)
Day’s Range― - ―
52-Week Range€2.25 - €3.45
Previous CloseN/A
Volume0.00
Average Volume (3M)180.00
Market Cap
€1.81B
Enterprise Value€21.72B
Total Cash (Recent Filing)€55.90M
Total Debt (Recent Filing)€281.69M
Price to Earnings (P/E)49.2
Beta0.52
Next Earnings
Feb 11, 2027EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding527,306,150
10 Day Avg. Volume3
30 Day Avg. Volume180
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)2.10
Price to Sales (P/S)3.45
P/FCF Ratio16.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.97Price Target Upside20.17% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€42.92M
Bulls Say, Bears Say
Bulls Say
Improving ProfitabilityThe sustained expansion in operating and net margins indicates that Vimian is converting revenue into earnings more effectively than in 2023. If maintained, stronger profitability can improve internal funding capacity, support investment across its veterinary businesses, and provide greater resilience against slower sales growth.
Lower LeverageA materially lower debt-to-equity ratio gives Vimian a healthier financial base and greater flexibility to fund operations or pursue growth without relying as heavily on borrowing. Reduced leverage also lowers balance-sheet pressure if veterinary demand or operating conditions weaken over the next several quarters.
Diversified Veterinary Health ModelExposure to several veterinary health categories and customer groups creates a broader platform than reliance on a single product line. Diagnostics, pharmaceuticals, equipment, and consumables can support recurring professional demand, while the multi-brand portfolio and established distribution channels reinforce market reach.
Bears Say
Cooling Revenue GrowthRecent revenue expansion has slowed substantially compared with earlier periods, increasing the importance of continued margin improvement to sustain earnings growth. If sales momentum remains modest, Vimian may have fewer opportunities to leverage its operating platform and could face greater pressure to generate growth through efficiency.
Volatile Cash GenerationAlthough current free cash flow remains positive, the history of negative operating cash flow and the recent decline in free-cash-flow growth show that earnings do not consistently translate into expanding cash generation. Working-capital swings or investment timing could therefore constrain funding flexibility over the medium term.
Moderate Returns On CapitalImproving margins have not yet translated into high shareholder returns, suggesting that Vimian's equity and asset base is still producing only moderate profitability. This limits the efficiency of retained capital and means further earnings improvement may require stronger growth or better asset utilization.
Vimian Group AB News
0V0 FAQ
What was Vimian Group AB’s price range in the past 12 months?
Vimian Group AB lowest stock price was €2.25 and its highest was €3.45 in the past 12 months.
What is Vimian Group AB’s market cap?
Vimian Group AB’s market cap is €1.81B.
When is Vimian Group AB’s upcoming earnings report date?
Vimian Group AB’s upcoming earnings report date is Feb 11, 2027 which is in 111 days.
How were Vimian Group AB’s earnings last quarter?
Vimian Group AB released its earnings results on Oct 22, 2026. The company reported €0.02 earnings per share for the quarter, missing the consensus estimate of €0.023 by -€0.003.
Is Vimian Group AB overvalued?
According to Wall Street analysts Vimian Group AB’s price is currently Undervalued.
Does Vimian Group AB pay dividends?
Vimian Group AB does not currently pay dividends.
What is Vimian Group AB’s EPS estimate?
Vimian Group AB’s EPS estimate is 0.03.
How many shares outstanding does Vimian Group AB have?
Vimian Group AB has 527,306,150 shares outstanding.
What happened to Vimian Group AB’s price movement after its last earnings report?
Vimian Group AB reported an EPS of €0.02 in its last earnings report, missing expectations of €0.023. Following the earnings report the stock price went up 3.393%.
Which hedge fund is a major shareholder of Vimian Group AB?
Currently, no hedge funds are holding shares in DE:0V0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimian Group AB
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
0V0 Stock 12 Month Forecast
Average Price Target
€2.97
▲(20.17% Upside)
Technical Analysis
AddLife AB
―
CellaVision AB
―
Bactiguard Holding AB
―
Q-linea AB
―
Devyser Diagnostics AB
―